Latest news with #BrianMoriarty
Business Wire
14-07-2025
- Business
- Business Wire
Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis
NEW YORK & WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world's most advanced clinicogenomic dataset in rheumatoid arthritis (RA). The collaboration aims to generate high-resolution insights to support academic research, clinical trial design, therapeutic strategy, and real-world evidence generation. The collaboration centers on transforming real-world data from the electronic health records (EHRs) of patients tested with Scipher's clinically validated molecular signature test that predicts non-response to TNF inhibitor therapies, PrismRA ®. These data will be converted into structured, analysis-ready formats. By integrating deep genomic insights with comprehensive clinical context, the partnership aims to generate actionable real-world evidence to accelerate drug development in RA and related autoimmune conditions. 'Enormous potential is locked inside real-world clinical data, but much of it lives in an unstructured form,' said Brian Moriarty, Co-Founder of Savant Bio. 'By linking Scipher's validated genomic insights with structured patient journeys, we are creating the foundation for the next generation of real-world evidence to enable faster studies, richer evidence, and more targeted therapies in RA.' Savant's platform uses large language models (LLMs), paired with domain-specific quality controls, to extract structured variables from free-text clinical documentation, such as physician notes and pathology reports. Key enriched dimensions include biologic sequencing, disease activity scores (e.g., CDAI, DAS28), steroid exposure, radiographic findings, and treatment durability. Each output undergoes rigorous review to ensure accuracy and consistency and can be linked to claims, labs, and prescribing data for longitudinal analysis. 'As the leader in autoimmune transcriptomic data, we've long believed that combining molecular precision with real-world outcomes is key to advancing drug development in autoimmune disease,' said Reg Seeto, CEO of Scipher Medicine. 'By integrating structured clinical data through Savant's platform, we aim to enhance the utility of the growing Scipher dataset for applications ranging from trial design to market access — and ultimately support more personalized, evidence-driven treatment strategies in autoimmune diseases.' Initial structuring is underway on a cohort of more than 6,000 PrismRA-tested patients, creating one of the most comprehensive genomically defined RA cohorts with structured EHR data. Additional expansion is planned. The dataset will support critical use cases, including: Validating real-world predictors of treatment response Mapping treatment sequencing and disease control Building precision cohorts for post-TNFi trials Supporting post-market studies and label expansion The enriched dataset will be made available through collaborative research initiatives, co-publications, and structured licensing partnerships. Interested organizations are encouraged to engage early to help shape use cases and gain preliminary access to insights. About Scipher Medicine Scipher Medicine is redefining drug development in autoimmune diseases through its precision diagnostics platform, real-world data, and network biology. The company's Prism ® platform uses genomic signatures to guide therapeutic selection and generate insights into treatment response. Scipher has built the largest genomic biobank in RA, which is coupled with access to EHR data from a network of over 3 million rheumatology patients. Learn more at About Savant Bio Savant is transforming how healthcare and life sciences organizations unlock the value trapped in unstructured medical data. Its data abstraction platform combines advanced large language models with domain-specific quality controls to convert free-text clinical records into structured, analysis-ready data — efficiently, accurately, and at scale. Backed by Roivant, Savant partners with leading institutions across healthcare, life sciences, and research to deliver sharper insights and better outcomes. Learn more at
Yahoo
28-02-2025
- Business
- Yahoo
State Street, Apollo Debut Private-Debt ETF in Big Breakthrough
(Bloomberg) -- A novel private-credit ETF from State Street Corp. and Apollo Global Management Inc. started trading on Thursday, in a watershed moment for the $1.6 trillion industry. Cuts to Section 8 Housing Assistance Loom Amid HUD Uncertainty The Trump Administration Takes Aim at Transportation Research Shelters Await Billions in Federal Money for Homelessness Providers NYC's Congestion Pricing Pulls In $48.6 Million in First Month New York's Congestion Pricing Plan Faces Another Legal Showdown The SPDR SSGA Apollo IG Public & Private Credit ETF debuted on the New York Stock Exchange under the ticker 'PRIV.' The two finance behemoths appear to have gained ground over rivals by offering an ETF with outsized exposure to the asset class, after Apollo pledged to originate a portion of investments for the vehicle, while also helping to provide intra-day price data. While the ETF will cap investments deemed illiquid at 15% to conform to Securities and Exchange Commission requirements, its private-credit exposure is generally expected to comprise between 10% and 35% of the portfolio, the filing shows. 'This represents a seismic shift,' wrote Morningstar analyst Brian Moriarty in an online publication, who expects a boom in copycat funds. The agreement with Apollo amounts 'to a creative way around the SEC's definition of illiquid, thereby allowing the ETF to own more than the expected 15% limit,' he added. Bloomberg News first reported that PRIV was set to begin trading as soon as Thursday, after the fund's information was listed on the website of the New York exchange. Private credit has historically been illiquid and difficult to trade. Apollo, like some of its industry peers, has been looking to change all that by building a marketplace devoted to the asset class in a bid to change the assumption among regulators and market participants that it's inherently illiquid. So far, Apollo has traded about $2 billion of assets that it's originated and has about 60 active clients. Apollo Chief Executive Officer Marc Rowan has also made a case for private assets to be a core part of mass-market portfolios, including those owned by wealthy retail investors. The ETF may also 'achieve exposure' to private-credit instruments by investing in interval funds or business development companies, though these will be limited to 15% of its net assets, the filing shows. BDCs are publicly traded vehicles focused on investing in direct, often middle-market, loans. ETF Race State Street and Apollo's initial filing for PRIV in September made waves through the ETF industry, sparking a race to offer private-asset funds to the masses — in one form or the other. A handful of ETF issuers have introduced funds that mimic private-equity returns, while others have added this kind of exposure via special-purpose vehicles, though capped at the 15% threshold. 'We've seen some signs that there is a lot of unmet demand to get private assets in the ETF wrapper,' said Eric Balchunas of Bloomberg Intelligence. He pointed to demand for the ERShares Private-Public Crossover ETF (XOVR), which has had $130 million of inflows so far this year — fueled by its exposure to Elon Musk's SpaceX. While PRIV's launch is significant because it allows investors exposure to assets that were previously difficult to invest in, 'the main concern is how you value non-publicly traded assets in a publicly traded vehicle,' said Will Rhind, founder of ETF issuer GraniteShares. --With assistance from Laura Benitez. Trump's SALT Tax Promise Hinges on an Obscure Loophole Warner Bros. Movie Heads Are Burning Cash, and Their Boss Is Losing Patience Walmart Wants to Be Something for Everyone in a Divided America China Learned to Embrace What the US Forgot: The Virtues of Creative Destruction OXO Fought Back Against the Black Spatula Panic. People Defected Anyway ©2025 Bloomberg L.P. Sign in to access your portfolio
